Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,910,605

Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,910,605
Title:Non-imidazole alkylamines as histamine H.sub.3- receptor ligands and their therapeutic applications
Abstract: Use of a compound of formula (A), wherein: ##STR00001## W is a residue which imparts antagonistic and/or agonistic activity at histamine H.sub.3-receptors when attached to an imidazole ring in 4(5) position; R.sup.1 and R.sup.2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H.sub.3-receptors of histamine.
Inventor(s): Schwartz; Jean-Charles (Paris, FR), Arrang; Jean-Michel (Dourdon, FR), Garbarg; Monique (Paris, FR), Lecomte; Jeanne-Marie (Paris, FR), Ligneau; Xavier (Paris, FR), Schunack; Walter G. (Berlin, DE), Stark; Holger (Berlin, DE), Ganellin; Charon Robin (Welwyn, GB), Leurquin; Fabien (London, GB), Elz; Sigurd (Berlin, DE)
Assignee: Societe Civile Bioprojet (Paris, FR)
Application Number:11/478,682
Patent Claim Types:
see list of patent claims

Recent additions to Drugs Protected by US Patent 7,910,605

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 7,910,605

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,910,605

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98401944Jul 29, 1998
98403351Dec 31, 1998

International Family Members for US Patent 7,910,605

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 276751 ⤷  Free Forever Trial
Austria 326446 ⤷  Free Forever Trial
Australia 5511999 ⤷  Free Forever Trial
Belgium 2016C048 ⤷  Free Forever Trial
Canada 2321881 ⤷  Free Forever Trial
Germany 69920472 ⤷  Free Forever Trial
Germany 69931409 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.